13.94BMarket Cap11.60P/E (TTM)
3.640High3.580Low4.71MVolume3.590Open3.590Pre Close17.03MTurnover5.03252wk High0.23%Turnover Ratio3.85BShares3.55052wk Low0.312EPS TTM7.56BFloat Cap8.576Historical High15.02P/E (Static)2.09BShs Float0.017Historical Low0.241EPS LYR1.67%Amplitude0.15Dividend TTM0.45P/B100Lot Size4.14%Div YieldTTM
GENTING Stock Forum
Genting's investment in TauRx Pharmaceuticals focuses on the development of hydromethylthionine mesylate (HMTM), not a vaccine. HMTM is a drug designed to treat Alzheimer's disease .The drug recently completed Phase 3 clinical trials, showing promising results such as slowed cognitive decline and a strong safety profile.
The regulatory process has begun, with submissions made to the UK Medicines and Healthcare Products Regulatory Age...
No comment yet